Finnish🇫🇮 (Orion)innovation darolutamide(Nubeqa) was/is kind of s "game changer" treating prostate cancer. Also finnish🇫🇮 innovation (Orion) Opevesostat(MK-5684/ODM-208) is now on phase 3 study.It is likely to become new "game changer" for pca drug.Merck🇺🇲 and Orion 🇫🇮Announced Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Hope..Opevesostat (MK-5684; ODM-208).... - Advanced Prostate...
Hope..Opevesostat (MK-5684; ODM-208).Phase 3.
Written by
petrig
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Should go into the OMAHA2a ODM-208 (MK-5684-004): phase 3 trial?
I had my 3 monthly OC visit last week. Blood test is showing 0.3 up from 0.15 six weeks ago. MO...
PARP inhibitor Olaparib, phase 3 study findings (PROpel)
While we wait for the next generation PARP inhibitors to become available (I have written about it...
AMG 212 Phase 1 study shows potential.
ASCO 2019: Phase 1 Study of Pasotuxizumab, a PSMA-Targeting Bispecific T cell Engager Immunotherapy...
Phase 1 trial shows promising results for fractionated dose of 225Ac-J591 in PCa treatment
The fractionated dosing achieved promising results with 95% of patients experiencing any PSA...
New therapy (I hope I am not repeating myself)
https://www.urologytimes.com/view/antibody-drug-conjugate-plus-docetaxel-shows-promise-in-metastatic
Related Posts
ODM-208 (MK-5684): phase 3 trial started
combining Abiraterone with Avadart have synergistic benefit 
Is VERU-111 (Novel Oral Tubulin Inhibitor) similar to Fenbendazole or Mebendazole?- 1/4 dose enzalutamide for MCRPc working for 4 years in 87 yr. old
Trials NCT 03338790 or NCT02897375 Decided on NCT 03338790 trial
